Prevalence and Risk Factors of Sleep Disturbance in a Large HIV-Infected Adult Population.
This cross-sectional study evaluates the prevalence and factors associated with sleep disturbances in French adult HIV-infected outpatients. Patients fullfilled a self-administered questionnaire on their health behavior, sleep attitudes (Pittsburgh sleep quality index, PSQI), quality of life and depression; 1354 patients were enrolled. Median sleeping time was 7 h. Poor sleep quality was observed in 47 % of the patients, and moderate to serious depressive symptoms in 19.7 %. Factors significantly associated with sleep disturbances were depression, male gender, active employment, living single, tobacco-smoking, duration of HIV infection, nevirapine or efavirenz-including regimen. Prevalence of poor sleepers is high in this HIV adult outpatient population. Associated factors seem poorly specific to HIV infection and more related to social and psychological status. Taking care of these disturbances may prove to be an effective health management strategy.
Infectious Diseases Department, CHU Hôtel-Dieu, University of Nantes, Nantes, France. Clotilde.allavena@chu-nantes.fr.|COREVIH Pays de la Loire, Nantes, France. Clotilde.allavena@chu-nantes.fr.
C
C
Allavena
COREVIH Pays de la Loire, Nantes, France.|Infectious Diseases department, CHD Vendée, La Roche sur Yon, France.
T
T
Guimard
Infectious Diseases Department, CHU Hôtel-Dieu, University of Nantes, Nantes, France.|COREVIH Pays de la Loire, Nantes, France.
E
E
Billaud
CHU, Explorations fonctionnelles, University of Nantes, Nantes, France.
S
S
De la Tullaye
Infectious Diseases Department, CHU Hôtel-Dieu, University of Nantes, Nantes, France.|COREVIH Pays de la Loire, Nantes, France.
V
V
Reliquet
COREVIH Pays de la Loire, Nantes, France.
S
S
Pineau
Infectious Diseases Department, CHU Hôtel-Dieu, University of Nantes, Nantes, France.|COREVIH Pays de la Loire, Nantes, France.
H
H
Hüe
Infectious Diseases Department, CHU Hôtel-Dieu, University of Nantes, Nantes, France.|COREVIH Pays de la Loire, Nantes, France.
C
C
Supiot
COREVIH Pays de la Loire, Nantes, France.|Infectious Diseases Department, CHU, Angers, France.
J-M
JM
Chennebault
COREVIH Pays de la Loire, Nantes, France.|Internal Medicine Department, CH, St Nazaire, France.
C
C
Michau
COREVIH Pays de la Loire, Nantes, France.|Infectious Diseases Department, CH, Le Mans, France.
H
H
Hitoto
COREVIH Pays de la Loire, Nantes, France.|Internal Medicine Department, CH, Laval, France.
R
R
Vatan
Infectious Diseases Department, CHU Hôtel-Dieu, University of Nantes, Nantes, France.|COREVIH Pays de la Loire, Nantes, France.
F
F
Raffi
D000328:Adult; D019380:Anti-HIV Agents / Q000008:administration & dosage; D003430:Cross-Sectional Studies; D003863:Depression / Q000150:complications / Q000453:epidemiology*; D005260:Female; D005602:France / Q000453:epidemiology; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010045:Outpatients / Q000706:statistics & numerical data*; D015995:Prevalence; D011788:Quality of Life; D012307:Risk Factors; D012890:Sleep; D007319:Sleep Initiation and Maintenance Disorders / Q000150:complications / Q000453:epidemiology*; D012893:Sleep Wake Disorders / Q000175:diagnosis / Q000453:epidemiology*; D011795:Surveys and Questionnaires; D055815:Young Adult
D019380:Anti-HIV Agents
Depression; HIV infection; Insomnia; Sleep disturbance